Eli Lilly and Company $LLY Shares Purchased by BIP Wealth LLC

BIP Wealth LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 58.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,405 shares of the company’s stock after acquiring an additional 520 shares during the period. BIP Wealth LLC’s holdings in Eli Lilly and Company were worth $1,072,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Lazard Freres Gestion S.A.S. lifted its holdings in Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares during the period. Exencial Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after acquiring an additional 11,396 shares during the last quarter. Rede Wealth LLC bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $487,000. Precedent Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the period. Finally, Central Pacific Bank Trust Division boosted its position in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after purchasing an additional 1,843 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on LLY. Leerink Partners set a $1,234.00 price objective on Eli Lilly and Company in a report on Monday, January 5th. Bank of America lowered their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, CICC Research upped their target price on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s ovarian cancer candidate sofetabart (mipitecan), boosting the company’s oncology outlook and potential near-term regulatory value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: SURMOUNT-REAL UK phase 4 update supports real‑world evidence for tirzepatide’s obesity benefit, which helps validate long-term market adoption and pricing power for Lilly’s GLP-1/dual-agonist franchise. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Retatrutide trial shows potential knee osteoarthritis relief tied to obesity treatment, suggesting additional indications and expanded patient populations for Lilly’s obesity pipeline. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: Lilly launches a Phase 2 trial for a new oral drug targeting diabetic nerve pain, expanding non-GLP-1 growth avenues and diversifying future revenue streams. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Lilly confirmed its Q4 2025 results and investor call for Feb. 4, giving the market a near-term event to reset guidance and expectations. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Analysts at Guggenheim trimmed LLY’s price target marginally (from $1,163 to $1,161) but kept a buy rating—little change to consensus upside but worth noting as analyst attention remains high. LLY: price target lowered by Guggenheim
• Neutral Sentiment: Market pieces and retrospectives highlight strong historical returns and positive analyst narratives (e.g., MarketBeat, Benzinga), supporting investor confidence but not constituting new catalysts. Here’s How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
• Negative Sentiment: Commentary on Novo Nordisk’s new CEO and competitive strategy raises the profile of intense GLP-1 rivalry; investors may be watching pricing, market share, and promotional dynamics between LLY and Novo. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Eli Lilly and Company Stock Performance

LLY opened at $1,078.98 on Thursday. The company has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.79, a P/E/G ratio of 0.78 and a beta of 0.35. The business’s 50-day moving average price is $1,055.07 and its two-hundred day moving average price is $876.57. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.